Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation–Supported West Coast Prostate Cancer Dream Team

Rahul Aggarwal; Tomasz M. Beer; Martin Gleave; Joshua M. Stuart; Matthew Rettig; Christopher P. Evans; Jack Youngren; Joshi J. Alumkal; Jiaoti Huang; George Thomas; Owen Witte; Eric J. Small

doi:10.1016/j.euf.2016.10.011

Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation–Supported West Coast Prostate Cancer Dream Team

Rahul Aggarwal, Tomasz M. Beer, Martin Gleave, Joshua M. Stuart, Matthew Rettig, Christopher P. Evans, Jack Youngren, Joshi J. Alumkal, Jiaoti Huang, George Thomas, Owen Witte, Eric J. Small

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

The Stand Up 2 Cancer/Prostate Cancer Foundation–funded West Coast Dream Team project is a prospective multi-institutional study focused on acquiring metastatic castration-resistant prostate cancer (mCRPC) biopsy tissue at the time of resistance to abiraterone or enzalutamide. It is the first large-scale study designed to analyze mCRPC tissue specifically in this patient population. Study accrual is on target, with 261 out of a planned 300 metastatic tumor biopsies performed by August 2016. Paired biopsies have been completed in 42 patients, with paired genomic data before and after therapy obtained in 26 cases. Accrual is expected to be complete by December 2016.

Original language	English (US)
Pages (from-to)	469-471
Number of pages	3
Journal	European Urology Focus
Volume	2
Issue number	5
DOIs	https://doi.org/10.1016/j.euf.2016.10.011
State	Published - Dec 1 2016

Keywords

(AR) pathway inhibitors
abiraterone
enzalutamide

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.euf.2016.10.011

Cite this

Aggarwal, R., Beer, T. M., Gleave, M., Stuart, J. M., Rettig, M., Evans, C. P., Youngren, J., Alumkal, J. J., Huang, J., Thomas, G., Witte, O., & Small, E. J. (2016). Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation–Supported West Coast Prostate Cancer Dream Team. European Urology Focus, 2(5), 469-471. https://doi.org/10.1016/j.euf.2016.10.011

Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation–Supported West Coast Prostate Cancer Dream Team. / Aggarwal, Rahul; Beer, Tomasz M.; Gleave, Martin et al.
In: European Urology Focus, Vol. 2, No. 5, 01.12.2016, p. 469-471.

Research output: Contribution to journal › Article › peer-review

Aggarwal, R, Beer, TM, Gleave, M, Stuart, JM, Rettig, M, Evans, CP, Youngren, J, Alumkal, JJ, Huang, J, Thomas, G, Witte, O & Small, EJ 2016, 'Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation–Supported West Coast Prostate Cancer Dream Team', European Urology Focus, vol. 2, no. 5, pp. 469-471. https://doi.org/10.1016/j.euf.2016.10.011

@article{3ee07d2c784b4b3caaf9105b96b2baff,

title = "Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation–Supported West Coast Prostate Cancer Dream Team",

abstract = "The Stand Up 2 Cancer/Prostate Cancer Foundation–funded West Coast Dream Team project is a prospective multi-institutional study focused on acquiring metastatic castration-resistant prostate cancer (mCRPC) biopsy tissue at the time of resistance to abiraterone or enzalutamide. It is the first large-scale study designed to analyze mCRPC tissue specifically in this patient population. Study accrual is on target, with 261 out of a planned 300 metastatic tumor biopsies performed by August 2016. Paired biopsies have been completed in 42 patients, with paired genomic data before and after therapy obtained in 26 cases. Accrual is expected to be complete by December 2016.",

keywords = "(AR) pathway inhibitors, abiraterone, enzalutamide",

author = "Rahul Aggarwal and Beer, {Tomasz M.} and Martin Gleave and Stuart, {Joshua M.} and Matthew Rettig and Evans, {Christopher P.} and Jack Youngren and Alumkal, {Joshi J.} and Jiaoti Huang and George Thomas and Owen Witte and Small, {Eric J.}",

note = "Publisher Copyright: {\textcopyright} 2016 European Association of Urology",

year = "2016",

month = dec,

day = "1",

doi = "10.1016/j.euf.2016.10.011",

language = "English (US)",

volume = "2",

pages = "469--471",

journal = "European Urology Focus",

issn = "2405-4569",

publisher = "Elsevier BV",

number = "5",

}

TY - JOUR

T1 - Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer

T2 - Update on the Stand Up 2 Cancer/Prostate Cancer Foundation–Supported West Coast Prostate Cancer Dream Team

AU - Aggarwal, Rahul

AU - Beer, Tomasz M.

AU - Gleave, Martin

AU - Stuart, Joshua M.

AU - Rettig, Matthew

AU - Evans, Christopher P.

AU - Youngren, Jack

AU - Alumkal, Joshi J.

AU - Huang, Jiaoti

AU - Thomas, George

AU - Witte, Owen

AU - Small, Eric J.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - The Stand Up 2 Cancer/Prostate Cancer Foundation–funded West Coast Dream Team project is a prospective multi-institutional study focused on acquiring metastatic castration-resistant prostate cancer (mCRPC) biopsy tissue at the time of resistance to abiraterone or enzalutamide. It is the first large-scale study designed to analyze mCRPC tissue specifically in this patient population. Study accrual is on target, with 261 out of a planned 300 metastatic tumor biopsies performed by August 2016. Paired biopsies have been completed in 42 patients, with paired genomic data before and after therapy obtained in 26 cases. Accrual is expected to be complete by December 2016.

AB - The Stand Up 2 Cancer/Prostate Cancer Foundation–funded West Coast Dream Team project is a prospective multi-institutional study focused on acquiring metastatic castration-resistant prostate cancer (mCRPC) biopsy tissue at the time of resistance to abiraterone or enzalutamide. It is the first large-scale study designed to analyze mCRPC tissue specifically in this patient population. Study accrual is on target, with 261 out of a planned 300 metastatic tumor biopsies performed by August 2016. Paired biopsies have been completed in 42 patients, with paired genomic data before and after therapy obtained in 26 cases. Accrual is expected to be complete by December 2016.

KW - (AR) pathway inhibitors

KW - abiraterone

KW - enzalutamide

UR - http://www.scopus.com/inward/record.url?scp=85006827267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006827267&partnerID=8YFLogxK

U2 - 10.1016/j.euf.2016.10.011

DO - 10.1016/j.euf.2016.10.011

M3 - Article

AN - SCOPUS:85006827267

SN - 2405-4569

VL - 2

SP - 469

EP - 471

JO - European Urology Focus

JF - European Urology Focus

IS - 5

ER -

Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation–Supported West Coast Prostate Cancer Dream Team

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this